A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis
Article Abstract:
Adverse skin reactions and ineffectiveness of therapy seem to be the most common short-term and long-term reasons for stopping gold treatment in patients with rheumatoid arthritis (RA). Researchers evaluated the patterns for stopping gold therapy in 376 patients with RA over a 10-year period. Overall, the most common reason given for stopping gold therapy was ineffectiveness. The most common reason given within the first three years of treatment was skin reactions in mucous linings. Half of all the patients stopped therapy within the first 18 months of treatment. By 10 years, 92% of the patients had stopped the gold therapy. Reasons given for stopping gold therapy did not predict the reasons for stopping the second and third choices of treatment.
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Antibody deficiency associated with gold treatment: natural history and management in 22 patients
Article Abstract:
Gold treatment may cause antibody deficiency more commonly than currently thought. Twenty-two patients of one rheumatologist over a 10-year period, or about 2% of all patients undergoing gold treatment, developed antibody deficiencies. Half the cases were mild and did not necessitate discontinuing therapy, but half resulted in severe deficiency. Six of these patients developed serious infections. Discontinuing gold treatment resulted in antibody recovery in nine patients. Most patients had been having gold treatment for two or more years before developing antibody deficiency. Antibody production should be periodically monitored in patients undergoing gold treatment.
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate
Article Abstract:
Patients with rheumatoid arthritis who withdraw from drug therapy involving parenteral gold salts because they cannot tolerate the side effects continue their improvement at almost the same rate as patients who continue taking either gold salts or methotrexate. Those who withdraw from methotrexate use have a recurrence of the disease. The majority of patients involved in long-term drug trials withdraw from the tests. Therefore, it is relevant to inquire as to what happens when the medication is discontinued.
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Uterine innervation after hysterectomy for chronic pelvic pain with, and without, endometriosis
- Abstracts: Setting up a foot clinic. Leg ulceration in rheumatoid arthritis. Diabetic foot ulceration
- Abstracts: Allergies to transgenic foods - questions of policy. Treatment of allergic asthma with monoclonal anti-IgE antibody
- Abstracts: Antigenically different subtype in new flu vaccine. Volunteers in typhoid infection study will aid future vaccine development
- Abstracts: National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, April 1994-March 1995